#ASH17: Blue­print el­bows its way to cen­ter ring with ear­ly da­ta and a plan to seek quick FDA OK

Blue­print Med­i­cines $BPMC jumped on­to the radar at ASH on Sun­day, out­lin­ing some re­mark­able da­ta on their lead drug as the biotech lays the foun­da­tion for a reg­is­tra­tion pro­gram with the FDA. The Cam­bridge, MA-based biotech, which went pub­lic in 2015 and has a mar­ket cap that’s grown to $2.8 bil­lion, def­i­nite­ly wants to get the word out.

In­ves­ti­ga­tors for the com­pa­ny re­port­ed that their lead drug — avapri­tinib, for­mer­ly known as BLU-285 — hit an im­pres­sive 72% over­all re­sponse rate for rare cas­es of ad­vanced sys­temic mas­to­cy­to­sis and a 100% dis­ease con­trol rate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.